Literature DB >> 2824938

Development of leukemia and lymphosarcoma induced by bovine leukemia virus in sheep: a hematopathological study.

S Djilali1, A L Parodi, D Levy, G L Cockerell.   

Abstract

The hematological and neoplastic disorders induced in sheep by experimental bovine leukemia virus (BLV) infection are described. Seventeen of 19 BLV-inoculated sheep developed a marked increase in peripheral blood lymphocytes by 36 months after the intraperitoneal injection of peripheral blood lymphocytes from a BLV-infected cow. This increase correlated with an increase in the number of circulating B lymphocytes as demonstrated by the presence of surface immunoglobulins (SIg) and a high cell proliferative response to lipopolysaccharide and was considered to be a persistent B cell lymphocytosis. Lymphosarcoma developed in five BLV-infected sheep between 19 and 38 months postinoculation and was preceded in four out of five of these cases by an elevation in peripheral blood lymphocytes which began 4 to 26 months before death due to lymphosarcoma. The majority of tumor cells in all lymphosarcoma cases were of the centroblastic type, and in two cases in which the presence of SIg was assayed, the majority of tumor cells were SIg-positive. Thus, BLV-induced lymphosarcoma in sheep seems to be a B lymphocyte-derived tumor.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2824938

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  16 in total

1.  Intestinal Shiga toxin-producing Escherichia coli bacteria mitigate bovine leukemia virus infection in experimentally infected sheep.

Authors:  Witold A Ferens; Rowland Cobbold; Carolyn J Hovde
Journal:  Infect Immun       Date:  2006-05       Impact factor: 3.441

2.  Detection of a novel bovine lymphotropic herpesvirus.

Authors:  J Rovnak; S L Quackenbush; R A Reyes; J D Baines; C R Parrish; J W Casey
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Construction of a recombinant bovine leukemia virus vector for analysis of virus infectivity.

Authors:  D Derse; L Martarano
Journal:  J Virol       Date:  1990-01       Impact factor: 5.103

4.  The region between amino acids 245 and 265 of the bovine leukemia virus (BLV) tax protein restricts transactivation not only via the BLV enhancer but also via other retrovirus enhancers.

Authors:  S Tajima; Y Aida
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Proteome analysis of sheep B lymphocytes in the course of bovine leukemia virus-induced leukemia.

Authors:  Michal Reichert
Journal:  Exp Biol Med (Maywood)       Date:  2017-04-24

6.  Pathogenicity of molecularly cloned bovine leukemia virus.

Authors:  J Rovnak; A L Boyd; J W Casey; M A Gonda; W A Jensen; G L Cockerell
Journal:  J Virol       Date:  1993-12       Impact factor: 5.103

7.  The YXXL sequences of a transmembrane protein of bovine leukemia virus are required for viral entry and incorporation of viral envelope protein into virions.

Authors:  K Inabe; M Nishizawa; S Tajima; K Ikuta; Y Aida
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

8.  Latency of viral expression in vivo is not related to CpG methylation in the U3 region and part of the R region of the long terminal repeat of bovine leukemia virus.

Authors:  Shigeru Tajima; Masako Tsukamoto; Yoko Aida
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  A mutant form of the tax protein of bovine leukemia virus (BLV), with enhanced transactivation activity, increases expression and propagation of BLV in vitro but not in vivo.

Authors:  Shigeru Tajima; Masahiko Takahashi; Shin-Nosuke Takeshima; Satoru Konnai; Shan Ai Yin; Shinobu Watarai; Yoshimasa Tanaka; Misao Onuma; Kosuke Okada; Yoko Aida
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

10.  Low numbers of intestinal Shiga toxin-producing E. coli correlate with a poor prognosis in sheep infected with bovine leukemia virus.

Authors:  Witold A Ferens; Julius Haruna; Rowland Cobbold; Carolyn J Hovde
Journal:  J Vet Sci       Date:  2008-12       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.